Dual role of tumor suppressor p53 in regulation of DNA replication and oncogene E6-promoter activity of Epidermodysplasia verruciformis-associated human papillomavirus type 8

Virology

Volumn 308, Issue 2, 2003, Pages 279-290

  Akgül, Baki ^a   Karle, Peter ^b   Adam, Maja ^a   Fuchs, Pawel G ^a   Pfister, Herbert J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Epidermodysplasia verruciformis; HPV; HPV8 E2 protein; Origin of DNA replication; Tumor suppressor p53

Indexed keywords

PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DNA BINDING; DNA REPLICATION; EPIDERMODYSPLASIA VERRUCIFORMIS; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENOME ANALYSIS; INSECT CELL; MOLECULAR CLONING; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; UNTRANSLATED REGION; VIRUS ONCOGENE; VIRUS REPLICATION; WART VIRUS;

EPIDERMODYSPLASIA VERRUCIFORMIS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 8; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0344406206     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(02)00133-2     Document Type: Article

References (47)

1. Androphy E.J., Lowy D.R., Schiller J.T. Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature. 325:1987;70-73.
2. Berg M., Stenlund A. Functional interactions between papillomavirus E1 and E2 proteins. J. Virol. 71:1997;3853-3863.
3. Bonne-Andrea C., Tillier F., McShan G.D., Wilson V.G., Clertant P. Bovine papillomavirus type 1 DNA replication the transcriptional activator E2 acts in vitro as a specificity factor . J. Virol. 71:1997;6805-6815.
4. Chow L.T., Broker T. Papillomavirus DNA replication. Intervirology. 37:1994;150-158.
5. DePamphilis M.L. Eukaryotic DNA replication anatomy of an origin . Annu. Rev. Biochem. 62:1993;29-63.
6. de Wet J.R., Wood K.V., DeLuca M., Helinski D.R., Subramani S. Firefly luciferase gene structure and expression in mammalian cells . Mol. Cell. Biol. 7:1987;725-737.
7. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Human genomic DNA sequences define a consensus DNA binding site for p53. Nature Genet. 1:1992;45-49.
8. Ensser A., Pfister H. Epidermodysplasia verruciformis associated human papillomaviruses present a subgenus-specific organization of the regulatory genome region. Nucleic Acids Res. 18:1990;3919-3922.
9. Enzenauer C., Mengus G., Lavigne A.C., Davidson I., Pfister H., May M. Interaction of human papillomavirus 8 regulatory proteins E2, E6 and E7 with components of the TFIID complex. Intervirology. 41:1998;80-90.
10. Flores E.R., Lambert P.F. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J. Virol. 71:1997;7167-7179.
11. Fuchs P.G., Iftner T., Weninger J., Pfister H. Epidermodysplasia verruciformis-associated human papillomavirus 8 genomic sequence and comparative analysis . J. Virol. 58:1986;626-634.
12. Fuchs, P.G., Pfister, H., 1997. Molecular biology of HPV and mechanisms of keratinocyte transformation, in: Gross, G., von Krogh (Eds.), Human Papillomavirus Infections in Dermatovenerology, CRC Press, Boca Raton, FL, pp. 15-46.
13. Gopalakrishnan V., Khan S.A. E1 protein of human papillomavirus type 1a is sufficient for initiation of viral DNA replication. Proc. Natl. Acad. Sci. USA. 91:1994;9597-9601.
14. Haller K., Stubenrauch F., Pfister H. Differentiation-dependent transcription of the Epidermodysplasia verruciformis-associated human papillomavirus type 5 in benign lesions. Virology. 214:1995;245-255.
15. Helander S.D., Peters M.S., Pittelkow M.R. Expression of p53 in benign and malignant epidermal pathologic conditions. J. Am. Acad. Dermatol. 29:1993;741-748.
16. Horn S., Pfister H., Fuchs P.G. Constitutive transcriptional activator of Epidermodysplasia verruciformis-associated human papillomavirus 8. Virology. 196:1993;674-681.
17. Howley, P.M., Lowy, D.R. 2001. Papillomaviruses and their replication, in: Fields Virology, fourth ed. Lippincott Williams Wilkins, Philadelphia, PA, pp. 2197-2229.
18. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
19. Iftner T., Bierfelder S., Csapo Z., Pfister H. Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J. Virol. 62:1988;3655-3661.
20. Krubke J., Kraus J., Delius H., Chow L., Broker T., Iftner T., Pfister H. Genetic relationship among human papillomaviruses associated with benign and malignant tumours of patients with epidermodysplasia verruciformis. J. Gen. Virol. 68:1987;3091-3103.
21. Lambert P.F. Papillomavirus DNA replication. J. Virol. 65:1991;3417-3420.
22. Lee D., Kim H., Lee Y., Choe J. Identification of sequence requirement for the origin of DNA replication in human papillomavirus type 18. Virus Res. 52:1997;97-108.
23. Lepik D., Ilves I., Kristjuhan A., Maimets T., Ustav M. p53 protein is a suppressor of papillomavirus DNA amplificational replication. J. Virol. 72:1998;6822-6831.
24. Li R., Knight J., Bream G., Stenlund A., Botchan M. Specific recognition nucleotides and their DNA context determine the affinity of E2 protein for 17 binding sites in the BPV1 genome. Genes Dev. 3:1989;510-526.
25. Lu J.Z.-J., Sun Y.-N., Rose R.C., Bonnez W., McCance D.J. Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human Papillomavirus type 11 origin. J. Virol. 67:1993;7131-7139.
26. Massimi P., Pim D., Bertoli C., Bouvard V., Banks L. Interaction between the HPV16-E2 transcriptional activator and p53. Oncogene. 18:1999;7748-7754.
27. May M., Hebl V., Pfister H., Fuchs P.G. Unique topography of DNA-protein interactions in the non-coding region of epidermodysplasia verruciformis-associated human papillomaviruses. J. Gen. Virol. 72:1991;2989-2997.
28. May M., Grassmann K., Pfister H., Fuchs P.G. Transcriptional silencer of the human papillomavirus type 8 late promoter interacts alternatively with the viral trans activator E2 or with a cellular factor. J. Virol. 68:1994;3612-3619.
29. Myers G., Baker C., Münger K., Sverdrup F., McBride A., Bernard H.U. Human Papillomaviruses. 1997;Los Alamos National Laboratory, Los Alamos, New Mexico.
30. Newhouse C.D., Silverstein S.J. Orientation of a novel DNA binding site affects human papillomavirus-mediated transcription and replication. J. Virol. 75:2001;1722-1735.
31. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-707.
32. O'Conner, M., Chan, S.V., Bernard, H.U., 1995. Transcription binding sites in the long control region of genital HPVs. Human Papillomaviruses Database Compendium, Los Alamos.
33. Padlewska K., Ramoz N., Cassonnet P., Riou G., Barrois M., Majewski S., Croissant O., Jablonska S., Orth G. Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis. J. Invest. Dermatol. 117:2001;935-942.
34. Pajunk H.S., May C., Pfister H., Fuchs P.G. Regulatory interactions of transcription factor YY1 with control sequences of the E6 promoter of human papillomavirus type 8. J. Gen. Virol. 78:1997;3287-3295.
35. Pizarro A., Gamallo C., Castrsana J.S., Gomez L., Palacios J., Benito N., Espada J., Fonseca E., Contreras F. p53 protein expression in viral warts from patients with epidermodysplasia verruciformis. Br. J. Dermatol. 132:1995;513-519.
36. Purdie K., Sexton C.J., Proby C.M., Glover M.T., Williams A.T., Stables J.N., Leigh I.M. Malignant transformation of cutaneous lesions in renal allograft patients a role of human papillomavirus? Cancer Res. 53:1993;5328-5333.
37. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 protein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
38. Sedman J., Stenlund A. The papillomavirus E1 protein forms a DNA-dependent hexameric complex with ATPase and DNA helicase activities. J. Virol. 72:1998;6893-6897.
39. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:1990;6565-6577.
40. Steger G., Pfister H. In vitro expressed HPV8 E6 protein does not bind p53. Arch. Virol. 125:1992;355-360.
41. Stenlund A. Papillomavirus DNA replication. De Pamphilis M.L. DNA Replication in Eukaryotic Cells. 1996;679-697 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
42. Stubenrauch F., Malejczyk J., Fuchs P.G., Pfister H. Late promoter of human papillomavirus type 8 and its regulation. J. Virol. 66:1992;3485-3493.
43. Stubenrauch F., Pfister H. Low-affinity E2 binding site mediated downregulation of E2 transactivation of the human papillomavirus type 8 late promoter. J. Virol. 68:1994;6959-6966.
44. Sverdrup F., Khan S. Two E2 binding sites alone are sufficient to function as the minimal origin of replication of human papillomavirus type 18 DNA. J. Virol. 69:1995;1319-1323.
45. Ustav M., Stenlund A. Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. EMBO J. 10:1991;449-457.
46. Yang L., Botchan M. Replication of bovine papillomavirus type 1 DNA initiates within an E2-responsive enhancer element. J. Virol. 64:1990;5903-5911.
47. Zimmermann H., Degenkolbe R., Bernhard H.U., O'Conner M.J. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:1999;6209-6219.